Clinical Trial

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2023-06-09; most recent amendment 2026-06-16.
Status change: Recruiting → Active, Not Recruiting 2024-11-26
Status change: Not Yet Recruiting → Recruiting 2023-07-26
Trial Details
NCT Number NCT05909904
Lead Sponsor BeiGene
Conditions Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Enrollment 160 participants
Start Date 2023-08-02
Primary Completion 2025-06-17 (estimated)
Study Completion 2026-07-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-14